Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours ยท Estimated delivery Aug 12 - Aug 17
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
Diabetes Obes Metab (2018) 20(1):20005
Mood Enhancement: B12 plays a role in the production of neurotransmitters like serotonin, which contributes to mood regulation
The best peptides for weight loss overview helps contextualize where each compound fits within the broader landscape of options
Complete local surgical resection can prolong survival of patients with MPNST and improve treatment prognosis
Imaging features and treatment of an intradural lumbar cystic schwannomaI
US$ 27.00
US$ 20.77
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 22.04
US$ 27.50
US$ 20.26
US$ 28.00
US$ 22.16
